The diagnostic and therapeutic potential of targeting the galectin family and c-MET signaling pathways offers promising avenues for more effective treatment approaches in various cancers, potentially enhancing diagnostic accuracy and patient care in clinical practice. This evidence concerns the gene MET and cancer.